Sabby Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Sabby Management’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,914	Closed	-$223K	–	344
2016 Q4	$208K	Sell	10,914 -1,262	-10%	-$24.1K	0.01%	239
2016 Q3	$238K	Sell	12,176 -88,624	-88%	-$1.5M	0.01%	266
2016 Q2	$1.51M	Buy	100,800 +54,445	+117%	+$684K	0.08%	129
2016 Q1	$426K	Buy	+46,355	New	+$562K	0.02%	220

Other funds holding FLXN

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Sabby Management's FLXN Position: Q1 2017 in Review

Sabby Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q1 2017, closing a stake of 10,914 shares — an estimated $223K sold.

Sabby Management first reported a position in FLXN in Q1 2016 and held it in 4 quarters. The position peaked at $1.51M in Q2 2016. 100 funds tracked by Wall St. Rank hold FLXN as of Q1 2017.

Sabby Management reported no remaining Flexion Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Sabby Management sold 10,914 Flexion Therapeutics, Inc. shares in Q1 2017, an estimated $223K.
Sabby Management first reported a position in Flexion Therapeutics, Inc. in Q1 2016 and held it in 4 quarters.
Sabby Management's Flexion Therapeutics, Inc. position peaked at $1.51M in Q2 2016.
100 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q1 2017.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.